Daily Stock Analysis, CPIX, Cumberland Pharmaceuticals Inc, priceseries

Cumberland Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.98
Close
4.85
High
4.98
Low
4.80
Previous Close
4.98
Daily Price Gain
-0.13
YTD High
6.99
YTD High Date
May 20, 2019
YTD Low
4.70
YTD Low Date
Sep 4, 2019
YTD Price Change
-1.59
YTD Gain
-24.69%
52 Week High
6.99
52 Week High Date
May 20, 2019
52 Week Low
4.70
52 Week Low Date
Sep 4, 2019
52 Week Price Change
-1.51
52 Week Gain
-23.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 16. 2019
6.00
May 31. 2019
6.32
10 Trading Days
5.39%
Link
LONG
Sep 19. 2019
5.29
Sep 24. 2019
5.58
3 Trading Days
5.58%
Link
LONG
Sep 25. 2019
5.34
Oct 7. 2019
5.62
8 Trading Days
5.15%
Link
Company Information
Stock Symbol
CPIX
Exchange
NasdaqGS
Company URL
http://www.cumberlandpharma.com
Company Phone
615-255-0068
CEO
A. J. Kazimi
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001087294
About

Cumberland Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of branded prescription products. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, and Ethyol. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. The company's product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. Its pre-approval products consist of Methotrexate injection for treating active rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as disabling psoriasis; and Totect injection for emergency oncology intervention, which helps to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc, Nordic Group B.V., and Cumberland Emerging Technologies. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.